ASH 2010 - pick of abstracts
Novel CML Drug Active After Failures of Imatinib, Dasatinib, and Nilotinib
Elsevier Global Medical News. 2010 Dec 6, JS MacNeil
Novel CML Drug Active After Failures of Imatinib, Dasatinib, and Nilotinib
You are here
Oncologystat- CML The Changing Landscape: Interview with Prof. Apperley-Parts 1 and 2
CML—The Changing Landscape of Front-line Therapy: Part I: Interview With Dr. Jane Apperley
CML—The Changing Landscape of Front-line Therapy: Part I: Interview With Dr. Jane Apperley
ASH 2010 - Orlando
Chronic Myeloid Leukemia: An Historical Perspective
Chronic Myeloid Leukemia: An Historical Perspective
Michael W. Deininger
Nature News- Cellular 'alchemy' transforms skin into blood 7/11/2010
Published online 7 November 2010 | Nature | doi:10.1038/news.2010.588
Published online 7 November 2010 | Nature | doi:10.1038/news.2010.588
Advances in the Treatment and Management of Patients With CML: A Nurse's Perspective CE Patricia S. Ault, MSN, RN
Editor's Note:
Chronic myeloid leukemia (CML) represents approximately 11% of all adult forms of leukemia, and in 2009, approximately 5050 cases were diagnosed in the United States.[1] Imatinib, which targets a constitutively active tyrosine kinase encoded by the chimeric BCR-ABL1 oncogene, was approved for use in 2001 and has been shown to induce durable responses and an overall survival rate of 89% at 5 years.[2]
Editor's Note:
Chronic myeloid leukemia (CML) represents approximately 11% of all adult forms of leukemia, and in 2009, approximately 5050 cases were diagnosed in the United States.[1] Imatinib, which targets a constitutively active tyrosine kinase encoded by the chimeric BCR-ABL1 oncogene, was approved for use in 2001 and has been shown to induce durable responses and an overall survival rate of 89% at 5 years.[2]
Second-Generation BCR-ABL Kinase Inhibitors in CML
CORRESPONDENCE Second-Generation BCR-ABL Kinase Inhibitors in CML; N Engl J Med 2010; 363:1672-1675October 21, 2010
CORRESPONDENCE Second-Generation BCR-ABL Kinase Inhibitors in CML; N Engl J Med 2010; 363:1672-1675October 21, 2010
CHMP positive recommendation for use of Tasigna in Newly Diagnosed Ph+ CML
Changing the Culture of Clinical Trials: Reviving a Failing Effort
Changing the Culture of Clinical Trials: Reviving a Failing Effort
2010 Sept 22, Lee Schwartzberg, MD, FACP, Editor-in-Chief
Cancer research is in big trouble. Surprised? Take issue with this statement? Yes, we know vastly more about what makes a cancer cell tick than we did a decade ago. A technical tour de force such as fully sequencing the cancer genome has been successfully performed, not just once but a dozen times. Not a day goes by without a report on personalized cancer care coming soon to a clinic near you. So what’s the problem?
Changing the Culture of Clinical Trials: Reviving a Failing Effort
2010 Sept 22, Lee Schwartzberg, MD, FACP, Editor-in-Chief
Cancer research is in big trouble. Surprised? Take issue with this statement? Yes, we know vastly more about what makes a cancer cell tick than we did a decade ago. A technical tour de force such as fully sequencing the cancer genome has been successfully performed, not just once but a dozen times. Not a day goes by without a report on personalized cancer care coming soon to a clinic near you. So what’s the problem?
NEJM article: “Liberating the NHS” — Another Attempt to Implement Market Forces in English Health Care
Nick Black, M.D.- N Engl J Med 2010; 363:1103-1105September 16, 2010
Nick Black, M.D.- N Engl J Med 2010; 363:1103-1105September 16, 2010
New BCR/Abl Inhibitor from Ariad Pharmaceuticals
Ponatinib (AP24534) Pivotal Trial in Drug-Resistant or Intolerant Chronic Myeloid Leukemia
Ariad's new drug for CML is now in clinical trial and has Orphan drug status from FDA and EMA. www.ariad.com
Ponatinib (AP24534) Pivotal Trial in Drug-Resistant or Intolerant Chronic Myeloid Leukemia
Ariad's new drug for CML is now in clinical trial and has Orphan drug status from FDA and EMA. www.ariad.com